These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

184 related articles for article (PubMed ID: 37773632)

  • 1. Hyper-Dependence on NHEJ Enables Synergy between DNA-PK Inhibitors and Low-Dose Doxorubicin in Leiomyosarcoma.
    Marino-Enriquez A; Novotny JP; Gulhan DC; Klooster I; Tran AV; Kasbo M; Lundberg MZ; Ou WB; Tao DL; Pilco-Janeta DF; Mao VY; Zenke FT; Leeper BA; Gokhale PC; Cowley GS; Baker LH; Ballman KV; Root DE; Albers J; Park PJ; George S; Fletcher JA
    Clin Cancer Res; 2023 Dec; 29(24):5128-5139. PubMed ID: 37773632
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Inhibition of Aberrantly Overexpressed Polo-like Kinase 4 Is a Potential Effective Treatment for DNA Damage Repair-Deficient Uterine Leiomyosarcoma.
    Lee HHY; Chow KL; Wong HS; Chong TY; Wong AST; Cheng GHW; Ko JMK; Siu HC; Yeung MCF; Huen MSY; Tse KY; Bray MR; Mak TW; Leung SY; Ip PPC
    Clin Cancer Res; 2024 Sep; 30(17):3904-3918. PubMed ID: 38848043
    [TBL] [Abstract][Full Text] [Related]  

  • 3. PI3K/AKT/mTOR inhibition in combination with doxorubicin is an effective therapy for leiomyosarcoma.
    Babichev Y; Kabaroff L; Datti A; Uehling D; Isaac M; Al-Awar R; Prakesch M; Sun RX; Boutros PC; Venier R; Dickson BC; Gladdy RA
    J Transl Med; 2016 Mar; 14():67. PubMed ID: 26952093
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Preclinical Modeling of Leiomyosarcoma Identifies Susceptibility to Transcriptional CDK Inhibitors through Antagonism of E2F-Driven Oncogenic Gene Expression.
    Hemming ML; Bhola P; Loycano MA; Anderson JA; Taddei ML; Doyle LA; Lavrova E; Andersen JL; Klega KS; Benson MR; Crompton BD; Raut CP; George S; Letai A; Demetri GD; Sicinska E
    Clin Cancer Res; 2022 Jun; 28(11):2397-2408. PubMed ID: 35325095
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Integrated genomic and transcriptomic analysis revealed mutation patterns of de-differentiated liposarcoma and leiomyosarcoma.
    Liu W; Tong H; Zhang C; Zhuang R; Guo H; Lv C; Yang H; Lin Q; Guo X; Wang Z; Wang Y; Shen F; Wang S; Dai C; Wang G; Liu J; Lu W; Zhang Y; Zhou Y
    BMC Cancer; 2020 Oct; 20(1):1035. PubMed ID: 33115433
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Relationships between highly recurrent tumor suppressor alterations in 489 leiomyosarcomas.
    Schaefer IM; Lundberg MZ; Demicco EG; Przybyl J; Matusiak M; Chibon F; Ingram DR; Hornick JL; Wang WL; Bauer S; Baker LH; Lazar AJ; van de Rijn M; Mariño-Enríquez A; Fletcher JA
    Cancer; 2021 Aug; 127(15):2666-2673. PubMed ID: 33788262
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Targeting DNA Repair with Combined Inhibition of NHEJ and MMEJ Induces Synthetic Lethality in TP53-Mutant Cancers.
    Patterson-Fortin J; Bose A; Tsai WC; Grochala C; Nguyen H; Zhou J; Parmar K; Lazaro JB; Liu J; McQueen K; Shapiro GI; Kozono D; D'Andrea AD
    Cancer Res; 2022 Oct; 82(20):3815-3829. PubMed ID: 35972384
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Integrative genomic and transcriptomic analysis of leiomyosarcoma.
    Chudasama P; Mughal SS; Sanders MA; Hübschmann D; Chung I; Deeg KI; Wong SH; Rabe S; Hlevnjak M; Zapatka M; Ernst A; Kleinheinz K; Schlesner M; Sieverling L; Klink B; Schröck E; Hoogenboezem RM; Kasper B; Heilig CE; Egerer G; Wolf S; von Kalle C; Eils R; Stenzinger A; Weichert W; Glimm H; Gröschel S; Kopp HG; Omlor G; Lehner B; Bauer S; Schimmack S; Ulrich A; Mechtersheimer G; Rippe K; Brors B; Hutter B; Renner M; Hohenberger P; Scholl C; Fröhling S
    Nat Commun; 2018 Jan; 9(1):144. PubMed ID: 29321523
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Targeting TJP1 attenuates cell-cell aggregation and modulates chemosensitivity against doxorubicin in leiomyosarcoma.
    Lee EY; Yu JY; Paek AR; Lee SH; Jang H; Cho SY; Kim JH; Kang HG; Yun T; Oh SE; Park SY; You HJ
    J Mol Med (Berl); 2020 May; 98(5):761-773. PubMed ID: 32318747
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Targeted exome sequencing profiles genetic alterations in leiomyosarcoma.
    Agaram NP; Zhang L; LeLoarer F; Silk T; Sung YS; Scott SN; Kuk D; Qin LX; Berger MF; Antonescu CR; Singer S
    Genes Chromosomes Cancer; 2016 Feb; 55(2):124-30. PubMed ID: 26541895
    [TBL] [Abstract][Full Text] [Related]  

  • 11.
    Seligson ND; Kautto EA; Passen EN; Stets C; Toland AE; Millis SZ; Meyer CF; Hays JL; Chen JL
    Oncologist; 2019 Jul; 24(7):973-979. PubMed ID: 30541756
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Mocetinostat combined with gemcitabine for the treatment of leiomyosarcoma: Preclinical correlates.
    Lopez G; Braggio D; Zewdu A; Casadei L; Batte K; Bid HK; Koller D; Yu P; Iwenofu OH; Strohecker A; Choy E; Lev D; Pollock R
    PLoS One; 2017; 12(11):e0188859. PubMed ID: 29186204
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Genetic evidence for the involvement of DNA ligase IV in the DNA-PK-dependent pathway of non-homologous end joining in mammalian cells.
    Wang H; Zeng ZC; Perrault AR; Cheng X; Qin W; Iliakis G
    Nucleic Acids Res; 2001 Apr; 29(8):1653-60. PubMed ID: 11292837
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Identification of a Novel MAN1A1-ROS1 Fusion Gene Through mRNA-based Screening for Tyrosine Kinase Gene Aberrations in a Patient with Leiomyosarcoma.
    Suehara Y; Kohsaka S; Hayashi T; Akaike K; Kurisaki-Arakawa A; Sato S; Kobayashi E; Mizuno S; Ueno T; Morii T; Okuma T; Kurihara T; Hasegawa N; Sano K; Sasa K; Okubo T; Kim Y; Mano H; Saito T
    Clin Orthop Relat Res; 2021 Apr; 479(4):838-852. PubMed ID: 33196586
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Leiomyosarcomas: whole genome sequencing for a whole biology characterization.
    Chibon F; Darbo E; Pérot G
    Curr Opin Oncol; 2019 Jul; 31(4):317-321. PubMed ID: 31033567
    [TBL] [Abstract][Full Text] [Related]  

  • 16. DNA-Dependent Protein Kinase Inhibitor Peposertib Potentiates the Cytotoxicity of Topoisomerase II Inhibitors in Synovial Sarcoma Models.
    Revia S; Budzinska MA; Bogatyrova O; Neumann F; Zimmermann A; Amendt C; Albers J
    Cancers (Basel); 2023 Dec; 16(1):. PubMed ID: 38201616
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Loss of the DNA Repair Gene RNase H2 Identifies a Unique Subset of DDR-Deficient Leiomyosarcomas.
    Nakazawa MS; Silverman IM; Rimkunas V; Veloso A; Glodzik D; Johnson A; Ohsumi TK; Patel SR; Conley AP; Roland CL; Soliman PT; Beird HC; Wu CC; Ingram DR; Lazcano R; Song D; Wani KM; Lazar AJ; Yap TA; Wang WL; Livingston JA
    Mol Cancer Ther; 2024 Jul; 23(7):1057-1065. PubMed ID: 38561019
    [TBL] [Abstract][Full Text] [Related]  

  • 18. HPV51-associated Leiomyosarcoma: A Novel Class of TP53/RB1-Wildtype Tumor With Predilection for the Female Lower Reproductive Tract.
    Williams EA; Montesion M; Lincoln V; Tse JY; Hiemenz MC; Mata DA; Shah BB; Shoroye A; Alexander BM; Werth AJ; Foley-Peres K; Milante RR; Ross JS; Ramkissoon SH; Williams KJ; Adhikari LJ; Zuna RE; LeBoit PE; Lin DI; Elvin JA
    Am J Surg Pathol; 2022 Jun; 46(6):729-741. PubMed ID: 35034043
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Copper ions are novel therapeutic agents for uterine leiomyosarcoma.
    Kakuda M; Matsuzaki S; Ueda Y; Shiomi M; Matsuzaki S; Kimura T; Fujita M; Egawa-Takata T; Kobayashi E; Serada S; Yoshino K; Naka T; Kimura T
    Am J Obstet Gynecol; 2020 Jan; 222(1):64.e1-64.e16. PubMed ID: 31351063
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Establishment and characterization of NCC-LMS3-C1: a novel patient-derived cell line of leiomyosarcoma.
    Yoshimatsu Y; Noguchi R; Osaki J; Sin Y; Tsuchiya R; Ono T; Akiyama T; Adachi Y; Tanzawa Y; Yoshida A; Kawai A; Kondo T
    Hum Cell; 2024 Jan; 37(1):337-344. PubMed ID: 37907774
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.